Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indonesia Energy Corporation Limited (INDO) vs Moderna, Inc. (MRNA) Price & Performance

Indonesia Energy Corporation LimitedTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Indonesia Energy Corporation Limited vs Moderna, Inc. — how do they compare? Indonesia Energy Corporation Limited trades at $2.91 (market cap $45.55M), while Moderna, Inc. trades at $63.61 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 530.8× Indonesia Energy Corporation Limited's market cap, and Moderna, Inc. is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.

INDOMRNA
Market Cap
$45.55M$24.18B
Sector
EnergyHealth
52-Week High
$6.74$81.80
52-Week Low
$2.49$22.36
Enterprise Value
$40.92M$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Indonesia Energy Corporation Limited

Indonesia Energy Corporation (INDO) trades at $2.89, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company is actively drilling the K-29 well at its Kruh Block, indicating operational progress. Financially, it shows deep losses with a net income margin of -253.4% and negative ROE of -26.95% for 2025, though it beat EPS estimates in Q2 2025. Valuation metrics include a P/S of 21.57 and P/B of 2.32, reflecting high sales multiples amid profitability challenges.

The outlook hinges on successful well outcomes driving future revenue; current analyst consensus is 100% buy, but high execution risks and persistent losses pose significant threats to shareholder value. Investors face volatility from oil price swings and operational delays.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

About Indonesia Energy Corporation Limited

Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.

Read more on INDO

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA